Clinical Trial: Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors
Study Status: Active, not recruiting
Recruit Status: Unknown status
Study Type: Interventional
Official Title: A Prospective Multicenter Phase II Trial of Gemcitabine, Cisplatin, and Ifosfamide (GIP) in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors (NSGCT) and a Predicte
Brief Summary: This is a prospective multicenter phase II trial of gemcitabine, cisplatin, and ifosfamide (GIP) in patients with relapsed non-seminomatous germ-cell tumors (NSGCT) and a predicted favorable prognosis.
Detailed Summary:
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Current Primary Outcome: Complete response rate
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Toxicity
- Progression free survival
- Overall survival
Original Secondary Outcome:
- Toxicity
- Progression
- Free survival
- Overall survival
Information By: Gustave Roussy, Cancer Campus, Grand Paris
Dates:
Date Received: August 3, 2005
Date Started: December 2004
Date Completion:
Last Updated: September 7, 2006
Last Verified: September 2006